On July 16, 2025, Onconetix, Inc. finalized a merger agreement with Ocuvex Therapeutics, where Ocuvex will become a wholly owned subsidiary; following this, the pre-merger Company shareholders will hold 90% and Parent shareholders 10% of the combined company. Additionally, the conversion price of Series C preferred shares was reduced to $3.50 until July 31, 2025, as approved by all holders.